#USA #Washington, DC #Rivus Pharmaceuticals #HU6 #AASLD 2025

Rivus Pharmaceuticals to Present Clinical Data from Phase 2a M-ACCEL Trial

Rivus Pharmaceuticals, a leader in the field of biopharmaceuticals focused on obesity and related cardiometabolic diseases, has announced its plans to present clinical data derived from its Phase 2a M-ACCEL trial at the forthcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. This key event is scheduled to take place from November 7-11, 2025, in Washington, DC.

The clinical data focuses on HU6, a promising investigational therapy aimed at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). Rivus previously shared encouraging topline results from the trial back in June 2025, signaling strong potential for HU6. The upcoming presentation will occur in a late-breaking oral session, providing stakeholders and attendees exciting insights into the treatment's efficacy and safety profile.

Presentation Details

Particulars related to the oral presentation are as follows:

• - Abstract Title: HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH - Top-Line Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL)
• - Abstract Number: 5005
• - Format: Oral Presentation
• - Presenter: Dr. Mazen Noureddin, a respected Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board of the Summit and Pinnacle Clinical Research Networks
• - Presentation Date and Time: Monday, November 10, 2025, from 2:00 PM to 2:15 PM ET

In addition to the AASLD conference, Rivus will also showcase the first preclinical data on obesity from its Controlled Metabolic Accelerators (CMAs) pipeline at ObesityWeek 2025, occurring from November 4-7, 2025, in Atlanta, Georgia. The poster presentation will detail innovative findings regarding Oral Controlled-Metabolic Accelerator Drives Fat-Specific Weight Loss and Augments GLP-1 Effect, with details:

• - Abstract Number: 121
• - Format: Poster Presentation
• - Presenter: Dr. Sol Collado, Senior Director of Drug Discovery at Rivus Pharmaceuticals
• - Presentation Date and Time: Tuesday, November 4, 2025, from 7:30 PM to 8:30 PM ET

About the Phase 2a M-ACCEL Trial

The Phase 2a M-ACCEL trial is a randomized, double-blind, placebo-controlled study that evaluated the effects of HU6 at varying dosages of 150 mg, 300 mg, and 450 mg once daily over a period of 26 weeks. The trial included 212 participants who were randomized into groups receiving placebo or HU6, with criteria focusing on patients exhibiting liver fat levels of ≥8% as measured by MRI-PDFF and a VCTE score of 7-15 kPa, targeting fibrosis from stages F2 to F3. The primary objective measures included the percent change from baseline in liver fat observed at the six-month mark, with secondary analyses focusing on body weight changes, metabolic control, and inflammatory markers, among others.

Introduction to Controlled Metabolic Accelerators (CMAs)

Rivus Pharmaceuticals is at the forefront of developing a new class of therapies known as Controlled Metabolic Accelerators (CMAs). These oral medications are designed specifically for sustained, selective, muscle-maintaining weight loss, particularly in obese patients. Through advancements in mitochondrial biology, Rivus aims to leverage CMAs to induce a safe increase in resting metabolic rates, enhancing energy expenditure through fat utilization. The lead candidate, HU6, has already shown promising results in previous clinical trials associated with MASH, metabolic dysfunction-associated steatotic liver disease (MASLD), and heart failure with preserved ejection fraction (HFpEF). Alongside these developments, Rivus is advancing a robust pipeline of novel CMAs intended for obesity and related cardiovascular conditions.

About Rivus Pharmaceuticals

Founded to pioneer the treatment of obesity-related disorders, Rivus Pharmaceuticals has made significant strides in the biotechnology sector. The organization's commitment to developing effective therapeutic diets includes the innovation of CMAs, facilitating a transformative approach to managing body weight and overall cardiovascular health. As Rivus gears up for its presentations at AASLD 2025 and ObesityWeek, attention is rightly turned toward their efforts in combating one of the most pressing health issues of our time. For further information about Rivus Pharmaceuticals and its innovations, visit Rivus’ website.